Oded Foreman
Overview
Explore the profile of Oded Foreman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
4494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vandal M, Institoris A, Reveret L, Korin B, Gunn C, Hirai S, et al.
Neuron
. 2025 Feb;
PMID: 39892386
Polymorphisms in CD2-associated protein (CD2AP) predispose to Alzheimer's disease (AD), but the underlying mechanisms remain unknown. Here, we show that loss of CD2AP in cerebral blood vessels is associated with...
2.
Edwards Iii D, Pereira E, Castro-Jorge L, Nevarez J, Foreman O, Spindler K
J Virol
. 2025 Jan;
99(2):e0154524.
PMID: 39745442
Protein kinase R (PKR) is an interferon-induced antiviral protein activated by autophosphorylation in response to double strand DNA (dsRNA) and other stimuli. Activated PKR causes translation inhibition and apoptosis, and...
3.
Soung A, Kyauk R, Pandey S, Shen Y, Reichelt M, Lin H, et al.
Glia
. 2024 Nov;
73(4):773-787.
PMID: 39601128
Multiple lines of evidence indicate that mitochondrial dysfunction occurs in demyelinating diseases, such as multiple sclerosis (MS). Failure of remyelination is thought to be caused in part by a block...
4.
Schauer S, Cho C, Novikova G, Roth G, Lee J, Sharma A, et al.
Alzheimers Dement
. 2024 Aug;
20(9):5861-5888.
PMID: 39090679
Introduction: Triggering receptor expressed on myeloid cells 2 (TREM2) agonists are being clinically evaluated as disease-modifying therapeutics for Alzheimer's disease. Clinically translatable pharmacodynamic (PD) biomarkers are needed to confirm drug...
5.
Etxeberria A, Shen Y, Vito S, Silverman S, Imperio J, Lalehzadeh G, et al.
J Neurosci
. 2024 Jun;
44(29.
PMID: 38830764
Human genetics and preclinical studies have identified key contributions of TREM2 to several neurodegenerative conditions, inspiring efforts to modulate TREM2 therapeutically. Here, we characterize the activities of three TREM2 agonist...
6.
Dominguez S, Laufer B, Sengupta Ghosh A, Li Q, Ruggeri G, Emani M, et al.
iScience
. 2023 Nov;
26(11):108362.
PMID: 37965143
Heterozygous mutations in the granulin () gene are a leading cause of frontotemporal lobar degeneration with TDP-43 aggregates (FTLD-TDP). Polymorphisms in have been associated with disease risk in mutation carriers...
7.
Yang C, Harafuji N, Caldovic L, Yu W, Boddu R, Bhattacharya S, et al.
J Mol Med (Berl)
. 2023 Aug;
101(9):1141-1151.
PMID: 37584738
Autosomal-recessive polycystic kidney disease (ARPKD; MIM #263200) is a severe, hereditary, hepato-renal fibrocystic disorder that causes early childhood morbidity and mortality. Mutations in the polycystic kidney and hepatic disease 1...
8.
Wang Y, Wu T, Tsai M, Rezzonico M, Abdel-Haleem A, Xie L, et al.
Elife
. 2023 Aug;
12.
PMID: 37555828
Tumor progression locus 2 (TPL2) (MAP3K8) is a central signaling node in the inflammatory response of peripheral immune cells. We find that TPL2 kinase activity modulates microglial cytokine release and...
9.
Deng L, Dourado M, Reese R, Huang K, Shields S, Stark K, et al.
Neuron
. 2023 Jun;
111(17):2642-2659.e13.
PMID: 37352856
Loss-of-function mutations in Nav1.7, a voltage-gated sodium channel, cause congenital insensitivity to pain (CIP) in humans, demonstrating that Nav1.7 is essential for the perception of pain. However, the mechanism by...
10.
Byrnes A, Dominguez S, Yen C, Laufer B, Foreman O, Reichelt M, et al.
Mol Ther Nucleic Acids
. 2023 Jun;
32:773-793.
PMID: 37346977
Antisense oligonucleotide (ASO) therapeutics are being investigated for a broad range of neurological diseases. While ASOs have been effective in the clinic, improving productive ASO internalization into target cells remains...